Gender-Specific Differences in Skeletal Muscle 11β-HSD1 Expression Across Healthy Aging.

CONTEXT Cushing's syndrome is characterized by marked changes in body composition (sarcopenia, obesity, and osteoporosis) that have similarities with those seen in aging. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts glucocorticoids to their active form (cortisone to cortisol in humans), resulting in local tissue amplification of effect. OBJECTIVE To evaluate 11β-HSD1 expression and activity with age, specifically in muscle. To determine putative causes for increased activity with age and its consequences upon phenotypic markers of adverse aging. DESIGN Cross-sectional observational study. SETTING National Institute for Health Research-Wellcome Trust Clinical Research Facility, Birmingham, United Kingdom. PATIENTS OR OTHER PARTICIPANTS Healthy human volunteers age 20 to 81 years (n = 134; 77 women, 57 men). INTERVENTIONS Day attendance at research facility for baseline observations, body composition analysis by dual-energy x-ray absorptiometry, jump-plate mechanography, grip strength analysis, baseline biochemical profiling, urine collection, and vastus lateralis muscle biopsy. MAIN OUTCOME MEASURE(S) Skeletal muscle gene expression, urine steroid profile, bivariate correlations between expression/activity and phenotypic/biochemical variables. RESULTS Skeletal muscle 11β-HSD1 expression was increased 2.72-fold in women over 60 years of age compared to those aged 20-40 years; no differences were observed in men. There was a significant positive correlation between skeletal muscle 11β-HSD1 expression and age in women across the group (rho = 0.40; P = .009). No differences in expression of 11β-HSD type 2, glucocorticoid receptor, or hexose-6-phosphate dehydrogenase between age groups were observed in either sex. Urinary steroid markers of 11β-HSD1, 11β-HSD type 2, or 5α-reductase were similar between age groups. Skeletal muscle 11β-HSD1 expression was associated with reduced grip strength in both sexes and correlated positively with percentage of body fat, homeostasis model of assessment for insulin resistance, total cholesterol, LH, and FSH and negatively with bone mineral content and IGF-1 in women. CONCLUSIONS Skeletal muscle 11β-HSD1 is up-regulated with age in women and is associated with reduced grip strength, insulin resistance, and an adverse body composition profile. Selective inhibition of 11β-HSD1 may offer a novel strategy to prevent and/or reverse age-related sarcopenia.

[1]  A J Howie,et al.  Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[2]  P. Jenkins,et al.  Modulation of Cortisol Metabolism during Treatment of Acromegaly Is Independent of Body Composition and Insulin Sensitivity , 2001, Hormone Research in Paediatrics.

[3]  D. Laber,et al.  11 { beta }-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle , 2011 .

[4]  Lianne Abrahams,et al.  11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. , 2013, The Journal of clinical investigation.

[5]  J. Born,et al.  Basal secretory activity of the hypothalamo-pituitary-adrenocortical axis is enhanced in healthy elderly. An assessment during undisturbed night-time sleep. , 1994, European journal of endocrinology.

[6]  S. Hillier,et al.  Regulation of 11beta-hydroxysteroid dehydrogenase isoforms and glucocorticoid receptor gene expression in the rat uterus. , 1999, The Journal of endocrinology.

[7]  G. Reynolds,et al.  Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11β-Hydroxysteroid Dehydrogenase Type 1 , 2012, Endocrinology.

[8]  L. Nieman,et al.  Cushing’s Syndrome , 2019, Canadian Family Practice Guidelines.

[9]  D J Kupfer,et al.  Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. , 1996, The Journal of clinical endocrinology and metabolism.

[10]  Michael Biehl,et al.  Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors , 2011, The Journal of clinical endocrinology and metabolism.

[11]  Z. Balázs,et al.  Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. , 2005, American journal of physiology. Endocrinology and metabolism.

[12]  W. Inder,et al.  11β Hydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle , 2006 .

[13]  C. Shackleton.  Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  H. García,et al.  Age-related changes in 11β-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects. , 2013, American journal of hypertension.

[15]  P. Hayes,et al.  Cortisol Release From Adipose Tissue by 11β-Hydroxysteroid Dehydrogenase Type 1 in Humans , 2009, Diabetes.

[16]  T. Olsson,et al.  Estrogen Reduces 11β‐Hydroxysteroid Dehydrogenase Type 1 in Liver and Visceral, but Not Subcutaneous, Adipose Tissue in Rats , 2010, Obesity.

[17]  H. Husi,et al.  Increased Skeletal Muscle 11βHSD1 mRNA Is Associated with Lower Muscle Strength in Ageing , 2013, PloS one.

[18]  D. Phillips,et al.  Regulation of Glucocorticoid Receptor α and β Isoforms and Type I 11β-Hydroxysteroid Dehydrogenase Expression in Human Skeletal Muscle Cells: A Key Role in the Pathogenesis of Insulin Resistance? , 2001 .

[19]  R. Rabasa-Lhoret,et al.  Menopause and sarcopenia: A potential role for sex hormones. , 2011, Maturitas.

[20]  J. Spranger,et al.  Skeletal Muscle 11beta-HSD1 Controls Glucocorticoid-Induced Proteolysis and Expression of E3 Ubiquitin Ligases Atrogin-1 and MuRF-1 , 2011, PloS one.

[21]  M. Alemany.  Do the Interactions between Glucocorticoids and Sex Hormones Regulate the Development of the Metabolic Syndrome? , 2012, Front. Endocrin..

[22]  M. Tarnopolsky,et al.  Suction‐modified Bergström muscle biopsy technique: Experience with 13,500 procedures , 2011, Muscle & nerve.

[23]  Jeremy W Tomlinson,et al.  11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. , 2013, Endocrine reviews.

[24]  Katherine A. Hughes,et al.  Recycling Between Cortisol and Cortisone in Human Splanchnic, Subcutaneous Adipose, and Skeletal Muscle Tissues In Vivo , 2012, Diabetes.

[25]  T. Olsson,et al.  Tissue-Specific Increases in 11β-Hydroxysteroid Dehydrogenase Type 1 in Normal Weight Postmenopausal Women , 2009, PloS one.

[26]  M. Hughson,et al.  Regulation of 11 beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol. , 2003, American journal of physiology. Endocrinology and metabolism.

[27]  M. Cooper,et al.  Osteoblastic 11β‐Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Shalet,et al.  Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not oestrogen dependent , 2000, Clinical endocrinology.

[29]  T. Olsson,et al.  Edinburgh Research Explorer Association of 11-hydroxysteroid dehydrogenase type I expression and activity with estrogen receptor in adipose tissue from postmenopausal women , 2022 .

[30]  Jeremy W Tomlinson,et al.  11 (cid:1) -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response , 2004 .

[31]  I. Robinson,et al.  Sexual dimorphism of hepatic 11 beta-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. , 1994, The Journal of endocrinology.

[32]  L. Nieman,et al.  Cushing's syndrome , 2005 .

[33]  Zaki K Hassan-Smith,et al.  11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess , 2014, Proceedings of the National Academy of Sciences.

[34]  R. Ruff,et al.  Neuromuscular disorders in clinical practice , 2014 .

[35]  K. Manolopoulos,et al.  Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake , 2013, American journal of physiology. Endocrinology and metabolism.

[36]  S. Shalet,et al.  Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. , 2000, The Journal of clinical endocrinology and metabolism.

[37]  A. Boulton,et al.  Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity. , 1999, The Journal of clinical endocrinology and metabolism.

[38]  B. Khalid,et al.  Differential regulation of the oxidative 11β-hydroxysteroid dehydrogenase activity in testis and liver☆ , 2000, Steroids.

[39]  I. McEwan,et al.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. , 2012, Cancer research.

[40]  Jeremy W Tomlinson,et al.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. , 2007, The Journal of clinical endocrinology and metabolism.

[41]  R. Smith,et al.  Sex- and tissue- specific regulation of 11β-hydroxysteroid dehydrogenase mRNA , 1995, Molecular and Cellular Endocrinology.